Literature DB >> 17991436

Hypo-phosphorylation leads to nuclear retention of NF-kappaB p65 due to impaired IkappaBalpha gene synthesis.

Karin Hochrainer1, Gianfranco Racchumi, Josef Anrather.   

Abstract

Subcellular localization guided by IkappaBalpha is crucial for regulation of nuclear factor-kappaB function. Here, we show that p65 Rel homology domain phosphorylation mutants are transported into the nucleus after IkappaBalpha degradation, but as a consequence of lower IkappaBalpha levels their relocation to the cytosol is blocked. We demonstrate that phosphorylation of residues S205, S276, and S281 of p65 is not required for interaction between p65 and IkappaBalpha, but is pivotal for regulating cellular IkappaBalpha levels by positively affecting gene synthesis. Our findings indicate that reduction of phosphorylation leads to nuclear retention of p65, which might be partly responsible for altered transcriptional behavior of p65 serine mutants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17991436      PMCID: PMC2149890          DOI: 10.1016/j.febslet.2007.10.056

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  23 in total

Review 1.  Activators and target genes of Rel/NF-kappaB transcription factors.

Authors:  H L Pahl
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

2.  Dynamic shuttling of nuclear factor kappa B between the nucleus and cytoplasm as a consequence of inhibitor dissociation.

Authors:  F Carlotti; S K Dower; E E Qwarnstrom
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

3.  Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65.

Authors:  Rosemary Kiernan; Vanessa Brès; Raymond W M Ng; Marie-Pierre Coudart; Selma El Messaoudi; Claude Sardet; Dong-Yan Jin; Stephane Emiliani; Monsef Benkirane
Journal:  J Biol Chem       Date:  2002-11-04       Impact factor: 5.157

4.  The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation.

Authors:  Alexander Hoffmann; Andre Levchenko; Martin L Scott; David Baltimore
Journal:  Science       Date:  2002-11-08       Impact factor: 47.728

5.  Duration of nuclear NF-kappaB action regulated by reversible acetylation.

Authors:  W Fischle; E Verdin; W C Greene
Journal:  Science       Date:  2001-08-31       Impact factor: 47.728

6.  The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1.

Authors:  Haihong Zhong; Michael J May; Eijiro Jimi; Sankar Ghosh
Journal:  Mol Cell       Date:  2002-03       Impact factor: 17.970

Review 7.  Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway.

Authors:  N D Perkins
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

8.  Essential role of RelA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation.

Authors:  Angeles Duran; María T Diaz-Meco; Jorge Moscat
Journal:  EMBO J       Date:  2003-08-01       Impact factor: 11.598

9.  A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression.

Authors:  Vasiliki Anest; Julie L Hanson; Patricia C Cogswell; Kris A Steinbrecher; Brian D Strahl; Albert S Baldwin
Journal:  Nature       Date:  2003-06-05       Impact factor: 49.962

Review 10.  Nuclear factor-kappaB: its role in health and disease.

Authors:  Ashok Kumar; Yasunari Takada; Aladin M Boriek; Bharat B Aggarwal
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

View more
  8 in total

1.  Monoubiquitination of nuclear RelA negatively regulates NF-κB activity independent of proteasomal degradation.

Authors:  Karin Hochrainer; Gianfranco Racchumi; Sheng Zhang; Costantino Iadecola; Josef Anrather
Journal:  Cell Mol Life Sci       Date:  2012-01-20       Impact factor: 9.261

2.  Site-specific phosphorylation of the p65 protein subunit mediates selective gene expression by differential NF-κB and RNA polymerase II promoter recruitment.

Authors:  Karin Hochrainer; Gianfranco Racchumi; Josef Anrather
Journal:  J Biol Chem       Date:  2012-10-25       Impact factor: 5.157

3.  Ubiquitination of NF-κB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance.

Authors:  Chune Ren; Xue Han; Chao Lu; Tingting Yang; Pengyun Qiao; Yonghong Sun; Zhenhai Yu
Journal:  Cell Death Differ       Date:  2021-08-31       Impact factor: 12.067

4.  Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway.

Authors:  Jun-Kun Zhan; Pan Tan; Yan-Jiao Wang; Yi Wang; Jie-Yu He; Zhi-Yong Tang; Wu Huang; You-Shuo Liu
Journal:  Cardiovasc Diabetol       Date:  2014-11-19       Impact factor: 9.951

Review 5.  Controls of Nuclear Factor-Kappa B Signaling Activity by 5'-AMP-Activated Protein Kinase Activation With Examples in Human Bladder Cancer Cells.

Authors:  Bo-Hwa Choi; Da-Hyun Lee; Jin Kim; Ju-Hee Kang; Chang-Shin Park
Journal:  Int Neurourol J       Date:  2016-09-23       Impact factor: 2.835

6.  Characterization of Site-Specific Phosphorylation of NF-κB p65 in Retinal Cells in Response to High Glucose and Cytokine Polarization.

Authors:  Haoshen Shi; Elizabeth A Berger
Journal:  Mediators Inflamm       Date:  2018-04-26       Impact factor: 4.711

7.  Involvement of endothelial CK2 in the radiation induced perivascular resistant niche (PVRN) and the induction of radioresistance for non-small cell lung cancer (NSCLC) cells.

Authors:  Qianwen Li; Yan Zong; Ke Li; Xiaohua Jie; Jiaxin Hong; Xiaoshu Zhou; Bian Wu; Zhenyu Li; Sheng Zhang; Gang Wu; Rui Meng
Journal:  Biol Res       Date:  2019-04-16       Impact factor: 5.612

8.  Dynamic phosphorylation of RelA on Ser42 and Ser45 in response to TNFα stimulation regulates DNA binding and transcription.

Authors:  Francesco Lanucara; Connie Lam; Jelena Mann; Tom P Monie; Stefano A P Colombo; Stephen W Holman; James Boyd; Manohar C Dange; Derek A Mann; Michael R H White; Claire E Eyers
Journal:  Open Biol       Date:  2016-07       Impact factor: 6.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.